{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T15:52:40Z","timestamp":1783785160938,"version":"3.55.0"},"reference-count":168,"publisher":"Bentham Science Publishers Ltd.","issue":"14","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPD"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>Alzheimer\u00b4s disease (AD) is the most widespread dementia in the world, followed by vascular dementia. Since AD is a heterogeneous disease that shows several varied phenotypes, it is not easy to make an accurate diagnosis, so it arises when the symptoms are clear and the disease is already very advanced. Therefore, it is important to find out biomarkers for AD early diagnosis that facilitate treatment or slow down the disease. Classic biomarkers are obtained from cerebrospinal fluid and plasma, along with brain imaging by positron emission tomography. Attempts have been made to discover uncommon biomarkers from other body fluids, which are addressed in this update.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective:<\/jats:title><jats:p>This update aims to describe recent biomarkers from minimally invasive body fluids for the patients, such as saliva, urine, eye fluid or tears.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>Biomarkers were determined in patients versus controls by single tandem mass spectrometry, and immunoassays. Metabolites were identified by nuclear magnetic resonance, and microRNAs with genome-wide high-throughput real-time polymerase chain reaction-based platforms.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>Biomarkers from urine, saliva, and eye fluid were described, including peptides\/proteins, metabolites, and some microRNAs. The association with AD neuroinflammation and neurodegeneration was analyzed, highlighting the contribution of matrix metalloproteinases, the immune system and microglia, as well as the vascular system.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p>Unusual biomarkers have been developed, which distinguish each stage and progression of the disease, and are suitable for the early AD diagnosis. An outstanding relationship of biomarkers with neuroinflammation and neurodegeneration was assessed, clearing up concerns of the etiopathogenesis of AD.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1381612828666220413101929","type":"journal-article","created":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T05:28:05Z","timestamp":1650000485000},"page":"1152-1169","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Uncommon Noninvasive Biomarkers for the Evaluation and Monitoring of the Etiopathogenesis of Alzheimer's Disease"],"prefix":"10.2174","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4913-2181","authenticated-orcid":true,"given":"Alicia B.","family":"Pomilio","sequence":"first","affiliation":[{"name":"Departamento de Bioqu\u00edmica Cl\u00ednica, \u00c1rea Hematolog\u00eda, Hospital de Cl\u00ednicas \u201cJos\u00e9 de San Mart\u00edn\u201d, Universidad de Buenos Aires, Av. C\u00f3rdoba 2351, C1120AAF Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4276-2209","authenticated-orcid":true,"given":"Arturo A.","family":"Vitale","sequence":"additional","affiliation":[{"name":"Departamento de Bioqu\u00edmica Cl\u00ednica, \u00c1rea Hematolog\u00eda, Hospital de Cl\u00ednicas \u201cJos\u00e9 de San Mart\u00edn\u201d, Universidad de Buenos Aires, Av. C\u00f3rdoba 2351, C1120AAF Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8979-7631","authenticated-orcid":true,"given":"Alberto J.","family":"Lazarowski","sequence":"additional","affiliation":[{"name":"Departamento de Bioqu\u00edmica Cl\u00ednica, Facultad de Farmacia y Bioqu\u00edmica, Instituto de Fisiopatolog\u00eda y Bioqu\u00edmica Cl\u00ednica (INFIBIOC), Universidad de Buenos Aires, C\u00f3rdoba 2351, C1120AAF Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3389\/fnagi.2020.00265","volume":"12","year":"2020","unstructured":"d\u2019Errico P, Meyer-Luehmann M. Mechanisms of pathogenic tau and A\u03b2 protein spreading in Alzheimer\u2019s disease. Front Aging Neurosci 2020,12,265","journal-title":"Front Aging Neurosci"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/s41582-021-00520-w","volume":"17","author":"Hampel H.","year":"2021","unstructured":"Hampel H.; Cummings J.; Blennow K.; Gao P.; Jack C.R.; Vergallo A.; Developing the ATX(N) classification for use across the Alzheimer disease continuum. Nat Rev Neurol 2021,17(9),580-589","journal-title":"Nat Rev Neurol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/bs.pmbts.2019.07.006","volume":"168","author":"Blennow K.","year":"2019","unstructured":"Blennow K.; Zetterberg H.; Fluid biomarker-based molecular phenotyping of Alzheimer\u2019s disease patients in research and clinical settings. Prog Mol Biol Transl Sci 2019,168,3-23","journal-title":"Prog Mol Biol Transl Sci"},{"key":"ref=4","author":"Pomilio A.B.","year":"2021","unstructured":"Pomilio A.B.; Vitale A.A.; Lazarowski A.J.; Neuroproteomics chip-based mass spectrometry for Alzheimer\u2019s disease biomarkers \u2013 Update. Curr Pharm Des 2021","journal-title":"Curr Pharm Des"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"546","DOI":"10.3390\/cells10030546","volume":"10","author":"Vidal C.","year":"2021","unstructured":"Vidal C.; Zhang L.; An analysis of the neurological and molecular alterations underlying the pathogenesis of Alzheimer\u2019s disease. Cells 2021,10(3),546","journal-title":"Cells"},{"key":"ref=6","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2020.550514","volume":"12","author":"Puthusseryppady V.","year":"2020","unstructured":"Puthusseryppady V.; Emrich-Mills L.; Lowry E.; Patel M.; Hornberger M.; spatial disorientation in Alzheimer\u2019s disease: The missing path from virtual reality to real world. Front Aging Neurosci 2020,12","journal-title":"Front Aging Neurosci"},{"key":"ref=7","doi-asserted-by":"crossref","unstructured":"Diagnostic and Statistical Manual of Mental Disorders (DSM-5) American Psychiatric Association (APA)Available from: Accessed on 28 August 2021.","DOI":"10.1176\/appi.books.9780890425787"},{"key":"ref=8","unstructured":"Updates to DSM\u20135 Criteria, Text and ICD-10 Codes. American Psychiatric Association (APA)Available from: Accessed on 28 August 2021."},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1212\/WNL.0000000000002923","volume":"87","author":"Jack C.R.","year":"2016","unstructured":"Jack C.R.; Bennett D.A.; Blennow K.; A\/T\/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology 2016,87(5),539-547","journal-title":"Neurology"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"Jack C.R.","year":"2018","unstructured":"Jack C.R.; Bennett D.A.; Blennow K.; NIA-AA Research Framework: Toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement 2018,14(4),535-562","journal-title":"Alzheimers Dement"},{"key":"ref=11","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12026","volume":"12","author":"Allegri R.F.","year":"2020","unstructured":"Allegri R.F.; Chrem M\u00e9ndez P.; Calandri I.; Prognostic value of ATN Alzheimer biomarkers: 60-month follow-up results from the argentine Alzheimer\u2019s disease neuroimaging initiative. Alzheimers Dement (Amst) 2020,12(1)","journal-title":"Alzheimers Dement (Amst)"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1212\/CON.0000000000000700","volume":"25","author":"Rabinovici G.D.","year":"2019","unstructured":"Rabinovici G.D.; Late-onset Alzheimer disease. Continuum (Minneap Minn) 2019,25(1),14-33","journal-title":"Continuum (Minneap Minn)"},{"key":"ref=13","doi-asserted-by":"publisher","DOI":"10.1212\/NXG.0000000000000512","volume":"6","author":"Reitz C.","year":"2020","unstructured":"Reitz C.; Rogaeva E.; Beecham G.W.; Late-onset vs. nonmendelian early-onset Alzheimer disease: A distinction without a difference? Neurol Genet 2020,6(5)","journal-title":"Neurol Genet"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nrneurol.2012.263","volume":"9","author":"Liu C.C.","year":"2013","unstructured":"Liu C.C.; Liu C.C.; Kanekiyo T.; Xu H.; Bu G.; Apolipoprotein E and Alzheimer disease: Risk, mechanisms and therapy. Nat Rev Neurol 2013,9(2),106-118","journal-title":"Nat Rev Neurol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"222","DOI":"10.3390\/genes10030222","volume":"10","author":"Abondio P.","year":"2019","unstructured":"Abondio P.; Sazzini M.; Garagnani P.; The genetic variability of APOE in different human populations and its implications for longevity. Genes (Basel) 2019,10(3),222","journal-title":"Genes (Basel)"},{"key":"ref=16","doi-asserted-by":"publisher","DOI":"10.2174\/97898114051361190301","author":"Gil-Extremera B.","year":"2016","unstructured":"Gil-Extremera B.; Volume 3 of Recent Advances in Alzheimer Research Sharjah: Bentham Science Publishers 2016","journal-title":"Volume 3 of Recent Advances in Alzheimer Research Sharjah: Bentham Science Publishers"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"600","DOI":"10.3390\/biom11040600","volume":"11","author":"Valenza M.","year":"2021","unstructured":"Valenza M.; Facchinetti R.; Menegoni G.; Steardo L.; Scuderi C.; Alternative targets to fight Alzheimer\u2019s disease: Focus on astrocytes. Biomolecules 2021,11(4),600","journal-title":"Biomolecules"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"199","DOI":"10.2147\/JIR.S86958","volume":"9","author":"Bronzuoli M.R.","year":"2016","unstructured":"Bronzuoli M.R.; Iacomino A.; Steardo L.; Scuderi C.; Targeting neuroinflammation in Alzheimer\u2019s disease. J Inflamm Res 2016,9,199-208","journal-title":"J Inflamm Res"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.jalz.2019.09.001","volume":"16","author":"Antonell A.","year":"2020","unstructured":"Antonell A.; Tort-Merino A.; R\u00edos J.; Synaptic, axonal damage and inflammatory cerebrospinal fluid biomarkers in neurodegenerative dementias. Alzheimers Dement 2020,16(2),262-272","journal-title":"Alzheimers Dement"},{"key":"ref=20","first-page":"1003","volume":"1","author":"Kempuraj D.","year":"2016","unstructured":"Kempuraj D.; Thangavel R.; Natteru P.A.; Neuroinflammation induces neurodegeneration. J Neurol Neurosurg Spine 2016,1(1),1003","journal-title":"J Neurol Neurosurg Spine"},{"key":"ref=21","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/1245049","volume":"2016","author":"Di Meo S.","year":"2016","unstructured":"Di Meo S.; Reed T.T.; Venditti P.; Victor V.M.; Role of ROS and RNS sources in physiological and pathological conditions. Oxid Med Cell Longev 2016,2016","journal-title":"Oxid Med Cell Longev"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/s41591-020-0815-6","volume":"26","author":"Johnson E.C.B.","year":"2020","unstructured":"Johnson E.C.B.; Dammer E.B.; Duong D.M.; Large-scale proteomic analysis of Alzheimer\u2019s disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation. Nat Med 2020,26(5),769-780","journal-title":"Nat Med"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"244","DOI":"10.3389\/fnagi.2019.00244","volume":"11","author":"Garc\u00eda-Gonz\u00e1lez L.","year":"2019","unstructured":"Garc\u00eda-Gonz\u00e1lez L.; Pilat D.; Baranger K.; Rivera S.; Emerging alternative proteinases in APP metabolism and Alzheimer\u2019s disease pathogenesis: A focus on MT1-MMP and MT5-MMP. Front Aging Neurosci 2019,11,244","journal-title":"Front Aging Neurosci"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"7162","DOI":"10.1111\/febs.15701","volume":"288","author":"Bassiouni W.","year":"2021","unstructured":"Bassiouni W.; Ali M.A.M.; Schulz R.; Multifunctional intracellular matrix metalloproteinases: Implications in disease. FEBS J 2021,288(24),7162-7182","journal-title":"FEBS J"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1007\/s00018-019-03178-2","volume":"76","author":"Rivera S.","year":"2019","unstructured":"Rivera S.; Garc\u00eda-Gonz\u00e1lez L.; Khrestchatisky M.; Baranger K.; Metalloproteinases and their tissue inhibitors in Alzheimer\u2019s disease and other neurodegenerative disorders. Cell Mol Life Sci 2019,76(16),3167-3191","journal-title":"Cell Mol Life Sci"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.3390\/cells10082055","volume":"10","author":"Wiera G.","year":"2021","unstructured":"Wiera G.; Mozrzymas J.W.; Extracellular metalloproteinases in the plasticity of excitatory and inhibitory synapses. Cells 2021,10(8),2055","journal-title":"Cells"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.3390\/ijms22031413","volume":"22","author":"Behl T.","year":"2021","unstructured":"Behl T.; Kaur G.; Sehgal A.; Multifaceted role of matrix metalloproteinases in neurodegenerative diseases: Pathophysiological and therapeutic perspectives. Int J Mol Sci 2021,22(3),1413","journal-title":"Int J Mol Sci"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"10705","DOI":"10.1021\/acs.jmedchem.0c00352","volume":"63","author":"Zipfel P.","year":"2020","unstructured":"Zipfel P.; Rochais C.; Baranger K.; Rivera S.; Dallemagne P.; Matrix metalloproteinases as new targets in Alzheimer\u2019s disease: Opportunities and challenges. J Med Chem 2020,63(19),10705-10725","journal-title":"J Med Chem"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3390\/ph14020086","volume":"14","author":"Ciccone L.","year":"2021","unstructured":"Ciccone L.; Vandooren J.; Nencetti S.; Orlandini E.; Natural marine and terrestrial compounds as modulators of matrix metalloproteinases-2 (MMP-2) and MMP-9 in Alzheimer\u2019s disease. Pharmaceuticals (Basel) 2021,14(2),86","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref=30","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/908636","volume":"2014","author":"Wang X.X.","year":"2014","unstructured":"Wang X.X.; Tan M.S.; Yu J.T.; Tan L.; Matrix metalloproteinases and their multiple roles in Alzheimer\u2019s disease. BioMed Res Int 2014,2014","journal-title":"BioMed Res Int"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.matbio.2017.11.007","volume":"75-76","author":"Hannocks M.J.","year":"2019","unstructured":"Hannocks M.J.; Zhang X.; Gerwien H.; The gelatinases, MMP-2 and MMP-9, as fine tuners of neuroinflammatory processes. Matrix Biol 2019,75-76,102-113","journal-title":"Matrix Biol"},{"key":"ref=32","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/5573642","volume":"2021","author":"Durmanova V.","year":"2021","unstructured":"Durmanova V.; Javor J.; Parnicka Z.; Impact of MMP2 rs243865 and MMP3 rs3025058 polymorphisms on clinical findings in Alzheimer\u2019s disease patients. Mediators Inflamm 2021,2021","journal-title":"Mediators Inflamm"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"105.e1","DOI":"10.1016\/j.neurobiolaging.2021.03.011","volume":"104","author":"Hoogmartens J.","year":"2021","unstructured":"Hoogmartens J.; Hens E.; Engelborghs S.; Investigation of the role of matrix metalloproteinases in the genetic etiology of Alzheimer\u2019s disease. Neurobiol Aging 2021,104,105.e1-105.e6","journal-title":"Neurobiol Aging"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1093\/brain\/awy305","volume":"142","author":"Zhu B.L.","year":"2019","unstructured":"Zhu B.L.; Long Y.; Luo W.; MMP13 inhibition rescues cognitive decline in Alzheimer transgenic mice via BACE1 regulation. Brain 2019,142(1),176-192","journal-title":"Brain"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1080\/13543776.2021.1881481","volume":"31","author":"Lenci E.","year":"2021","unstructured":"Lenci E.; Cosottini L.; Trabocchi A.; Novel matrix metalloproteinase inhibitors: An updated patent review (2014-2020). Expert Opin Ther Pat 2021,31(6),509-523","journal-title":"Expert Opin Ther Pat"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1159\/000346509","volume":"4","author":"Beckert H.","year":"2013","unstructured":"Beckert H.; Halle A.; The innate immune system in Alzheimer\u2019s disease. Else Kr\u00f6ner-Fresenius Symp 2013,4,86-90","journal-title":"Else Kr\u00f6ner-Fresenius Symp"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.4103\/1673-5374.272571","volume":"15","author":"Gray S.C.","year":"2020","unstructured":"Gray S.C.; Kinghorn K.J.; Woodling N.S.; Shifting equilibriums in Alzheimer\u2019s disease: The complex roles of microglia in neuroinflammation, neuronal survival and neurogenesis. Neural Regen Res 2020,15(7),1208-1219","journal-title":"Neural Regen Res"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"957","DOI":"10.3390\/cells10040957","volume":"10","author":"Casali B.T.","year":"2021","unstructured":"Casali B.T.; Reed-Geaghan E.G.; Microglial function and regulation during development, homeostasis and Alzheimer\u2019s disease. Cells 2021,10(4),957","journal-title":"Cells"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.3390\/ijms22052780","volume":"22","author":"Sorrentino S.","year":"2021","unstructured":"Sorrentino S.; Ascari R.; Maderna E.; Microglial heterogeneity and its potential role in driving phenotypic diversity of Alzheimer\u2019s disease. Int J Mol Sci 2021,22(5),2780","journal-title":"Int J Mol Sci"},{"key":"ref=40","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2021.631827","volume":"13","author":"Chen Y.","year":"2021","unstructured":"Chen Y.; Hong T.; Chen F.; Sun Y.; Wang Y.; Cui L.; Interplay between microglia and Alzheimer\u2019s disease-focus on the most relevant risks: APOE genotype, sex and age. Front Aging Neurosci 2021,13","journal-title":"Front Aging Neurosci"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"5504","DOI":"10.1038\/s41380-021-01083-4","volume":"26","author":"Cisbani G.","year":"2021","unstructured":"Cisbani G.; Rivest S.; Targeting innate immunity to protect and cure Alzheimer\u2019s disease: Opportunities and pitfalls. Mol Psychiatry Epub ahead of print2021,26(10),5504-5515","journal-title":"Mol Psychiatry"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"365","DOI":"10.3389\/fncel.2018.00365","volume":"12","author":"Cardona S.M.","year":"2018","unstructured":"Cardona S.M.; Kim S.V.; Church K.A.; Role of the Fractalkine Receptor in CNS autoimmune inflammation: New approach utilizing a mouse model expressing the human CX3CR1I249\/M280 variant. Front Cell Neurosci 2018,12,365","journal-title":"Front Cell Neurosci"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1159\/000505625","volume":"19","author":"Klohs J.","year":"2019","unstructured":"Klohs J.; An integrated view on vascular dysfunction in Alzheimer\u2019s disease. Neurodegener Dis 2019,19(3-4),109-127","journal-title":"Neurodegener Dis"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40364-020-00258-5","volume":"9","author":"Park J.E.","year":"2021","unstructured":"Park J.E.; Lim D.S.; Cho Y.H.; Plasma contact factors as novel biomarkers for diagnosing Alzheimer\u2019s disease. Biomark Res 2021,9(1),5","journal-title":"Biomark Res"},{"key":"ref=45","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.648947","volume":"8","author":"Yaron J.R.","year":"2021","unstructured":"Yaron J.R.; Zhang L.; Guo Q.; Haydel S.E.; Lucas A.R.; Fibrinolytic serine proteases, therapeutic serpins and inflammation: Fire dancers and firestorms. Front Cardiovasc Med 2021,8","journal-title":"Front Cardiovasc Med"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1016\/j.bbamcr.2017.07.009","volume":"1864","author":"Weidmann H.","year":"2017","unstructured":"Weidmann H.; Heikaus L.; Long A.T.; Naudin C.; Schl\u00fcter H.; Renn\u00e9 T.; The plasma contact system, a protease cascade at the nexus of inflammation, coagulation and immunity. Biochim Biophys Acta Mol Cell Res 2017,1864(11)(11 Pt B),2118-2127","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.3389\/fimmu.2019.02046","volume":"10","author":"Maas C.","year":"2019","unstructured":"Maas C.; Plasminflammation-An emerging pathway to bradykinin production. Front Immunol 2019,10,2046","journal-title":"Front Immunol"},{"key":"ref=48","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12504","volume":"5","author":"Singh P.K.","year":"2021","unstructured":"Singh P.K.; Badimon A.; Chen Z.L.; Strickland S.; Norris E.H.; The contact activation system and vascular factors as alternative targets for Alzheimer\u2019s disease therapy. Res Pract Thromb Haemost 2021,5(4)","journal-title":"Res Pract Thromb Haemost"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1111\/jth.13209","volume":"14","author":"Zamolodchikov D.","year":"2016","unstructured":"Zamolodchikov D.; Renn\u00e9 T.; Strickland S.; The Alzheimer\u2019s disease peptide \u03b2-amyloid promotes thrombin generation through activation of coagulation factor XII. J Thromb Haemost 2016,14(5),995-1007","journal-title":"J Thromb Haemost"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/jth.14325","volume":"17","author":"de Maat S.","year":"2019","unstructured":"de Maat S.; Clark C.C.; Boertien M.; Factor XII truncation accelerates activation in solution. J Thromb Haemost 2019,17(1),183-194","journal-title":"J Thromb Haemost"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.pneurobio.2018.01.003","volume":"165-167","author":"Nokkari A.","year":"2018","unstructured":"Nokkari A.; Abou-El-Hassan H.; Mechref Y.; Implication of the Kallikrein-Kinin system in neurological disorders: Quest for potential biomarkers and mechanisms. Prog Neurobiol 2018,165-167,26-50","journal-title":"Prog Neurobiol"},{"key":"ref=52","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2020.104833","volume":"139","author":"Singh P.K.","year":"2020","unstructured":"Singh P.K.; Chen Z-L.; Ghosh D.; Strickland S.; Norris E.H.; Increased plasma bradykinin level is associated with cognitive impairment in Alzheimer\u2019s patients. Neurobiol Dis 2020,139","journal-title":"Neurobiol Dis"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1182\/blood-2016-03-705384","volume":"128","author":"Marcos-Contreras O.A.","year":"2016","unstructured":"Marcos-Contreras O.A.; Martinez de Lizarrondo S.; Bardou I.; Hyperfibrinolysis increases blood-brain barrier permeability by a plasmin- and bradykinin-dependent mechanism. Blood 2016,128(20),2423-2434","journal-title":"Blood"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/978-3-030-19515-1_7","volume":"2019","author":"Salimi H.","year":"2019","unstructured":"Salimi H.; Klein R.S.; Disruption of the blood-brain barrier during neuroinflammatory and neuroinfectious diseases. Neuroimmune Diseases 2019,2019,195-234","journal-title":"Neuroimmune Diseases"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.dadm.2018.06.008","volume":"10","author":"Yamamoto-Imoto H.","year":"2018","unstructured":"Yamamoto-Imoto H.; Zamolodchikov D.; Chen Z-L.; A novel detection method of cleaved plasma high-molecular-weight kininogen reveals its correlation with Alzheimer\u2019s pathology and cognitive impairment. Alzheimers Dement (Amst) 2018,10(1),480-489","journal-title":"Alzheimers Dement (Amst)"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11011-021-00814-4","volume":"37","author":"Ap\u00e1tiga-P\u00e9rez R.","year":"2021","unstructured":"Ap\u00e1tiga-P\u00e9rez R.; Soto-Rojas L.O.; Campa-C\u00f3rdoba B.B.; Neurovascular dysfunction and vascular amyloid accumulation as early events in Alzheimer\u2019s disease. Metab Brain Dis 2021,37,39-50","journal-title":"Metab Brain Dis"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.3390\/ijms22042022","volume":"22","author":"Soto-Rojas L.O.","year":"2021","unstructured":"Soto-Rojas L.O.; Pacheco-Herrero M.; Mart\u00ednez-G\u00f3mez P.A.; The neurovascular unit dysfunction in Alzheimer\u2019s disease. Int J Mol Sci 2021,22(4),2022","journal-title":"Int J Mol Sci"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1097\/MOH.0000000000000368","volume":"24","author":"Ahn H.J.","year":"2017","unstructured":"Ahn H.J.; Chen Z.L.; Zamolodchikov D.; Norris E.H.; Strickland S.; Interactions of \u03b2-amyloid peptide with fibrinogen and coagulation factor XII may contribute to Alzheimer\u2019s disease. Curr Opin Hematol 2017,24(5),427-431","journal-title":"Curr Opin Hematol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"9354","DOI":"10.1038\/s41598-021-88432-z","volume":"11","author":"Peacock R.B.","year":"2021","unstructured":"Peacock R.B.; McGrann T.; Tonelli M.; Komives E.A.; Serine protease dynamics revealed by NMR analysis of the thrombin-thrombomodulin complex. Sci Rep 2021,11(1),9354","journal-title":"Sci Rep"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.cmet.2020.03.005","volume":"31","year":"2020","unstructured":"Mitochondria-endoplasmic reticulum contacts in reactive astrocytes promote vascular remodeling Cell Metab 2020,31(4),791-808","journal-title":"Cell Metab"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.neuron.2019.01.014","volume":"101","author":"Merlini M.","year":"2019","unstructured":"Merlini M.; Rafalski V.A.; Rios Coronado P.E.; Fibrinogen induces microglia-mediated spine elimination and cognitive impairment in an Alzheimer\u2019s disease model. Neuron 2019,101(6),1099-1108.e6","journal-title":"Neuron"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"21812","DOI":"10.1073\/pnas.1010373107","volume":"107","author":"Ahn H.J.","year":"2010","unstructured":"Ahn H.J.; Zamolodchikov D.; Cortes-Canteli M.; Norris E.H.; Glickman J.F.; Strickland S.; Alzheimer\u2019s disease peptide beta-amyloid interacts with fibrinogen and induces its oligomerization. Proc Natl Acad Sci USA 2010,107(50),21812-21817","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1084\/jem.20131751","volume":"211","author":"Ahn H.J.","year":"2014","unstructured":"Ahn H.J.; Glickman J.F.; Poon K.L.; A novel A\u03b2-fibrinogen interaction inhibitor rescues altered thrombosis and cognitive decline in Alzheimer\u2019s disease mice. J Exp Med 2014,211(6),1049-1062","journal-title":"J Exp Med"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"4805","DOI":"10.3390\/ijms22094805","volume":"22","author":"Grossmann K.","year":"2021","unstructured":"Grossmann K.; Alzheimer\u2019s disease-rationales for potential treatment with the thrombin inhibitor Dabigatran. Int J Mol Sci 2021,22(9),4805","journal-title":"Int J Mol Sci"},{"key":"ref=65","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2020.625844","volume":"14","author":"Fan D.Y.","year":"2021","unstructured":"Fan D.Y.; Sun H.L.; Sun P.Y.; The correlations between plasma fibrinogen with amyloid-beta and tau levels in patients with Alzheimer\u2019s disease. Front Neurosci 2021,14","journal-title":"Front Neurosci"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"325","DOI":"10.5607\/en20042","volume":"29","author":"Seol W.","year":"2020","unstructured":"Seol W.; Kim H.; Son I.; Urinary biomarkers for neurodegenerative diseases. Exp Neurobiol 2020,29(5),325-333","journal-title":"Exp Neurobiol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.neulet.2008.02.019","volume":"435","author":"Takata M.","year":"2008","unstructured":"Takata M.; Nakashima M.; Takehara T.; Detection of amyloid beta protein in the urine of Alzheimer\u2019s disease patients and healthy individuals. Neurosci Lett 2008,435(2),126-130","journal-title":"Neurosci Lett"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.cca.2014.12.023","volume":"441","author":"Yoshida M.","year":"2015","unstructured":"Yoshida M.; Higashi K.; Kuni K.; Distinguishing mild cognitive impairment from Alzheimer\u2019s disease with acrolein metabolites and creatinine in urine. Clin Chim Acta 2015,441,115-121","journal-title":"Clin Chim Acta"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"19495","DOI":"10.1038\/srep19495","volume":"6","author":"Kimball B.A.","year":"2016","unstructured":"Kimball B.A.; Wilson D.A.; Wesson D.W.; Alterations of the volatile metabolome in mouse models of Alzheimer\u2019s disease. Sci Rep 2016,6(1),19495","journal-title":"Sci Rep"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1021\/acs.jproteome.7b00206","volume":"16","author":"Yu J.","year":"2017","unstructured":"Yu J.; Kong L.; Zhang A.; High-throughput metabolomics for discovering potential metabolite biomarkers and metabolic mechanism from the APPswe\/PS1dE9 transgenic model of Alzheimer\u2019s disease. J Proteome Res 2017,16(9),3219-3228","journal-title":"J Proteome Res"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"14244","DOI":"10.1038\/s41598-019-50837-2","volume":"9","author":"Pe\u00f1a-Bautista C.","year":"2019","unstructured":"Pe\u00f1a-Bautista C.; Vigor C.; Galano J.M.; New screening approach for Alzheimer\u2019s disease risk assessment from urine lipid peroxidation compounds. Sci Rep 2019,9(1),14244","journal-title":"Sci Rep"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/(SICI)1098-2825(1998)12:5<285:AID-JCLA6>3.0.CO;2-5","volume":"12","author":"Ghanbari H.","year":"1998","unstructured":"Ghanbari H.; Ghanbari K.; Beheshti I.; Munzar M.; Vasauskas A.; Averback P.; Biochemical assay for AD7C-NTP in urine as an Alzheimer\u2019s disease marker. J Clin Lab Anal 1998,12(5),285-288","journal-title":"J Clin Lab Anal"},{"key":"ref=73","first-page":"d989","volume":"7","author":"de la Monte S.M.","year":"2002","unstructured":"de la Monte S.M.; Wands J.R.; The AD7C-NTP neuronal thread protein biomarker for detecting Alzheimer\u2019s disease. Front Biosci 2002,7,d989-d996","journal-title":"Front Biosci"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jamda.2010.03.004","volume":"12","author":"Youn Y.C.","year":"2011","unstructured":"Youn Y.C.; Park K.W.; Han S.H.; Kim S.; Urine neural thread protein measurements in Alzheimer disease. J Am Med Dir Assoc 2011,12(5),372-376","journal-title":"J Am Med Dir Assoc"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3233\/JAD-170383","volume":"60","author":"Zhang N.","year":"2017","unstructured":"Zhang N.; Zhang L.; Li Y.; Urine AD7c-NTP predicts amyloid deposition and symptom of agitation in patients with Alzheimer\u2019s disease and mild cognitive impairment. J Alzheimers Dis 2017,60(1),87-95","journal-title":"J Alzheimers Dis"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"613","DOI":"10.3233\/JAD-180412","volume":"66","author":"Zhang F.","year":"2018","unstructured":"Zhang F.; Wei J.; Li X.; Ma C.; Gao Y.; Early candidate urine biomarkers for detecting Alzheimer\u2019s disease before amyloid-\u03b2 plaque deposition in an APP (swe)\/PSEN1dE9 transgenic mouse model. J Alzheimers Dis 2018,66(2),613-637","journal-title":"J Alzheimers Dis"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"421","DOI":"10.3233\/JAD-180261","volume":"65","author":"Yao F.","year":"2018","unstructured":"Yao F.; Hong X.; Li S.; Urine-based biomarkers for Alzheimer\u2019s disease identified through coupling computational and experimental methods. J Alzheimers Dis 2018,65(2),421-431","journal-title":"J Alzheimers Dis"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1159\/000496100","volume":"9","author":"Watanabe Y.","year":"2019","unstructured":"Watanabe Y.; Hirao Y.; Kasuga K.; Molecular network analysis of the urinary proteome of Alzheimer\u2019s disease patients. Dement Geriatr Cogn Disord Extra 2019,9(1),53-65","journal-title":"Dement Geriatr Cogn Disord Extra"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1159\/000509561","volume":"10","author":"Watanabe Y.","year":"2020","unstructured":"Watanabe Y.; Hirao Y.; Kasuga K.; Urinary Apolipoprotein C3 is a potential biomarker for Alzheimer\u2019s disease. Dement Geriatr Cogn Disord Extra 2020,10(3),94-104","journal-title":"Dement Geriatr Cogn Disord Extra"},{"key":"ref=80","doi-asserted-by":"publisher","DOI":"10.1177\/1533317519880369","volume":"35","author":"Ku B.D.","year":"2020","unstructured":"Ku B.D.; Kim H.; Kim Y.K.; Ryu H.U.; Comparison of urinary Alzheimer-associated neural thread protein (AD7c-NTP) levels between patients with amnestic and nonamnestic mild cognitive impairment. Am J Alzheimers Dis Other Demen 2020,35","journal-title":"Am J Alzheimers Dis Other Demen"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/nbt.1592","volume":"28","author":"Griffin N.M.","year":"2010","unstructured":"Griffin N.M.; Yu J.; Long F.; Label-free, normalized quantification of complex mass spectrometry data for proteomic analysis. Nat Biotechnol 2010,28(1),83-89","journal-title":"Nat Biotechnol"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"371","DOI":"10.3390\/diagnostics11020371","volume":"11","author":"Pawlik P.","year":"2021","unstructured":"Pawlik P.; B\u0142ochowiak K. The role of salivary biomarkers in the early diagnosis of Alzheimer\u2019s disease and Parkinson\u2019s disease. Diagnostics (Basel) 2021,11(2),371","journal-title":"Diagnostics (Basel)"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s40120-019-00168-1","volume":"8","author":"Ashton N.J.","year":"2019","unstructured":"Ashton N.J.; Ide M.; Zetterberg H.; Blennow K.; Salivary biomarkers for Alzheimer\u2019s disease and related disorders. Neurol Ther 2019,8(S2)(Suppl. 2),83-94","journal-title":"Neurol Ther"},{"key":"ref=84","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/4761054","volume":"2019","author":"Gleerup H.S.","year":"2019","unstructured":"Gleerup H.S.; Hasselbalch S.G.; Simonsen A.H.; Biomarkers for Alzheimer\u2019s disease in saliva: A systematic review. Dis Markers 2019,2019","journal-title":"Dis Markers"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"497","DOI":"10.3390\/jcm9020497","volume":"9","author":"Maciejczyk M.","year":"2020","unstructured":"Maciejczyk M.; Zalewska A.; Gerreth A.K.; Salivary redox biomarkers in selected neurodegenerative diseases. J Clin Med 2020,9(2),497","journal-title":"J Clin Med"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"245","DOI":"10.3390\/brainsci10040245","volume":"10","author":"Schepici G.","year":"2020","unstructured":"Schepici G.; Silvestro S.; Trubiani O.; Bramanti P.; Mazzon E.; Salivary biomarkers: Future approaches for early diagnosis of neurodegenerative diseases. Brain Sci 2020,10(4),245","journal-title":"Brain Sci"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"56","DOI":"10.2174\/1567205015666181022094924","volume":"16","author":"Fran\u00e7ois M.","year":"2019","unstructured":"Fran\u00e7ois M.; Bull C.F.; Fenech M.F.; Leifert W.R.; Current state of saliva biomarkers for aging and Alzheimer\u2019s disease. Curr Alzheimer Res 2019,16(1),56-66","journal-title":"Curr Alzheimer Res"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1111\/j.1601-0825.2010.01773.x","volume":"17","author":"Spielmann N.","year":"2011","unstructured":"Spielmann N.; Wong D.T.; Saliva: Diagnostics and therapeutic perspectives. Oral Dis 2011,17(4),345-354","journal-title":"Oral Dis"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.bj.2018.03.004","volume":"41","author":"Farah R.","year":"2018","unstructured":"Farah R.; Haraty H.; Salame Z.; Fares Y.; Ojcius D.M.; Said S.N.; Salivary biomarkers for the diagnosis and monitoring of neurological diseases. Biomed J 2018,41(2),63-87","journal-title":"Biomed J"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"3220","DOI":"10.1038\/s41598-018-21131-4","volume":"8","author":"Jasim H.","year":"2018","unstructured":"Jasim H.; Carlsson A.; Hedenberg-Magnusson B.; Ghafouri B.; Ernberg M.; Saliva as a medium to detect and measure biomarkers related to pain. Sci Rep 2018,8(1),3220","journal-title":"Sci Rep"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"369","DOI":"10.3233\/JAD-140513","volume":"42","author":"Femminella G.D.","year":"2014","unstructured":"Femminella G.D.; Rengo G.; Komici K.; Autonomic dysfunction in Alzheimer\u2019s disease: Tools for assessment and review of the literature. J Alzheimers Dis 2014,42(2),369-377","journal-title":"J Alzheimers Dis"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"18","DOI":"10.4081\/vl.2012.e6","volume":"1","author":"Brizzio E.","year":"2012","unstructured":"Brizzio E.; Castro M.; Narbaitz M.; Ulcerated hemosiderinic dyschromia and iron deposits within lower limbs treated with a topical application of biological chelator. Veins Lymphatics 2012,1(1),18-26","journal-title":"Veins Lymphatics"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"632","DOI":"10.3389\/fnins.2018.00632","volume":"12","author":"Liu J-L.","year":"2018","unstructured":"Liu J-L.; Fan Y-G.; Yang Z-S.; Wang Z.Y.; Guo C.; Iron and Alzheimer\u2019s disease: From pathogenesis to therapeutic implications. Front Neurosci 2018,12,632","journal-title":"Front Neurosci"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/1471-2377-10-108","volume":"10","author":"Bermejo-Pareja F.","year":"2010","unstructured":"Bermejo-Pareja F.; Antequera D.; Vargas T.; Molina J.A.; Carro E.; Saliva levels of Abeta1-42 as potential biomarker of Alzheimer\u2019s disease: A pilot study. BMC Neurol 2010,10(1),108","journal-title":"BMC Neurol"},{"key":"ref=95","doi-asserted-by":"publisher","DOI":"10.1117\/1.JBO.19.5.051205","volume":"19","author":"Kim C.B.","year":"2014","unstructured":"Kim C.B.; Choi Y.Y.; Song W.K.; Song K.B.; Antibody-based magnetic nanoparticle immunoassay for quantification of Alzheimer\u2019s disease pathogenic factor. J Biomed Opt 2014,19(5)","journal-title":"J Biomed Opt"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.3233\/JAD-160748","volume":"55","author":"Lee M.","year":"2017","unstructured":"Lee M.; Guo J.P.; Kennedy K.; McGeer E.G.; McGeer P.L.; A method for diagnosing Alzheimer\u2019s disease based on salivary amyloid-\u03b2 protein 42 levels. J Alzheimers Dis 2017,55(3),1175-1182","journal-title":"J Alzheimers Dis"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12883-018-1160-y","volume":"18","author":"Sabbagh M.N.","year":"2018","unstructured":"Sabbagh M.N.; Shi J.; Lee M.; Salivary beta amyloid protein levels are detectable and differentiate patients with Alzheimer\u2019s disease dementia from normal controls: Preliminary findings. BMC Neurol 2018,18(1),155","journal-title":"BMC Neurol"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"377","DOI":"10.3390\/jcm9020377","volume":"9","author":"McGeer P.L.","year":"2020","unstructured":"McGeer P.L.; Lee M.; Kennedy K.; McGeer E.G.; Saliva diagnosis as a disease predictor. J Clin Med 2020,9(2),377","journal-title":"J Clin Med"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3233\/JAD-2011-110731","volume":"27","author":"Shi M.","year":"2011","unstructured":"Shi M.; Sui Y.T.; Peskind E.R.; Salivary tau species are potential biomarkers of Alzheimer\u2019s disease. J Alzheimers Dis 2011,27(2),299-305","journal-title":"J Alzheimers Dis"},{"key":"ref=100","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0117810","volume":"10","author":"Lau H-C.","year":"2015","unstructured":"Lau H-C.; Lee I.K.; Ko P.W.; Non-invasive screening for Alzheimer\u2019s disease by sensing salivary sugar using Drosophila cells expressing gustatory receptor (Gr5a) immobilized on an extended gate ion-sensitive field-effect transistor (EG-ISFET) biosensor. PLoS One 2015,10(2)","journal-title":"PLoS One"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.dadm.2018.03.003","volume":"11","author":"Pekeles H.","year":"2018","unstructured":"Pekeles H.; Qureshi H.Y.; Paudel H.K.; Schipper H.M.; Gornistky M.; Chertkow H.; Development and validation of a salivary tau biomarker in Alzheimer\u2019s disease. Alzheimers Dement (Amst) 2018,11(1),53-60","journal-title":"Alzheimers Dement (Amst)"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.neurobiolaging.2018.06.014","volume":"70","author":"Ashton N.J.","year":"2018","unstructured":"Ashton N.J.; Ide M.; Sch\u00f6ll M.; No association of salivary total tau concentration with Alzheimer\u2019s disease. Neurobiol Aging 2018,70,125-127","journal-title":"Neurobiol Aging"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.dadm.2017.04.002","volume":"8","author":"Carro E.","year":"2017","unstructured":"Carro E.; Bartolom\u00e9 F.; Bermejo-Pareja F.; Early diagnosis of mild cognitive impairment and Alzheimer\u2019s disease based on salivary lactoferrin. Alzheimers Dement (Amst) 2017,8(1),131-138","journal-title":"Alzheimers Dement (Amst)"},{"key":"ref=104","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102834","volume":"57","author":"Gonz\u00e1lez-S\u00e1nchez M.","year":"2020","unstructured":"Gonz\u00e1lez-S\u00e1nchez M.; Bartolome F.; Antequera D.; Decreased salivary lactoferrin levels are specific to Alzheimer\u2019s disease. EBioMedicine 2020,57","journal-title":"EBioMedicine"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jalz.2013.12.020","volume":"11","author":"Welling M.M.","year":"2015","unstructured":"Welling M.M.; Nabuurs R.J.A.; van der Weerd L.; Potential role of antimicrobial peptides in the early onset of Alzheimer\u2019s disease. Alzheimers Dement 2015,11(1),51-57","journal-title":"Alzheimers Dement"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.clinbiochem.2003.10.007","volume":"37","author":"Sayer R.","year":"2004","unstructured":"Sayer R.; Law E.; Connelly P.J.; Breen K.C.; Association of a salivary acetylcholinesterase with Alzheimer\u2019s disease and response to cholinesterase inhibitors. Clin Biochem 2004,37(2),98-104","journal-title":"Clin Biochem"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1002\/gps.1882","volume":"23","author":"Boston P.F.","year":"2008","unstructured":"Boston P.F.; Gopalkaje K.; Manning L.; Middleton L.; Loxley M.; Developing a simple laboratory test for Alzheimer\u2019s disease: Measuring acetylcholinesterase in saliva - a pilot study. Int J Geriatr Psychiatry 2008,23(4),439-440","journal-title":"Int J Geriatr Psychiatry"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"ZC58","DOI":"10.7860\/JCDR\/2017\/21715.9192","volume":"11","author":"Bakhtiari S.","year":"2017","unstructured":"Bakhtiari S.; Moghadam N.B.; Ehsani M.; Mortazavi H.; Sabour S.; Bakhshi M.; Can salivary acetylcholinesterase be a diagnostic biomarker for Alzheimer? J Clin Diagn Res 2017,11(1),ZC58-ZC60","journal-title":"J Clin Diagn Res"},{"key":"ref=109","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/scd.12342","volume":"39","author":"Ahmadi-Motamayel F.","year":"2019","unstructured":"Ahmadi-Motamayel F.; Goodarzi M.T.; Tarazi S.; Vahabian M.; Evaluation of salivary acetylcholinesterase and pseudocholinesterase in patients with Alzheimer\u2019s disease: A case-control study. Spec Care Dentist 2019,39(1),39-44","journal-title":"Spec Care Dentist"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"16396","DOI":"10.1038\/s41598-020-73362-z","volume":"10","author":"Pe\u00f1a-Bautista C.","year":"2020","unstructured":"Pe\u00f1a-Bautista C.; Torres-Cuevas I.; Baquero M.; Early neurotransmission impairment in non-invasive Alzheimer Disease detection. Sci Rep 2020,10(1),16396","journal-title":"Sci Rep"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1159\/000452832","volume":"43","author":"Jackson T.A.","year":"2017","unstructured":"Jackson T.A.; Moorey H.C.; Sheehan B.; Maclullich A.M.; Gladman J.R.; Lord J.M.; Acetylcholinesterase activity measurement and clinical features of delirium. Dement Geriatr Cogn Disord 2017,43(1-2),29-37","journal-title":"Dement Geriatr Cogn Disord"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.jamda.2020.02.013","volume":"21","author":"Morandi A.","year":"2020","unstructured":"Morandi A.; Zambon A.; Di Santo S.G.; Understanding factors associated with psychomotor subtypes of delirium in older inpatients with dementia. J Am Med Dir Assoc 2020,21(4),486-492.e7","journal-title":"J Am Med Dir Assoc"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11357-007-9042-z","volume":"30","author":"Su H.","year":"2008","unstructured":"Su H.; Gornitsky M.; Geng G.; Diurnal variations in salivary protein carbonyl levels in normal and cognitively impaired human subjects. Age (Dordr) 2008,30,1-9","journal-title":"Age (Dordr)"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"96074","DOI":"10.1039\/C5RA19094K","volume":"5","author":"Liang Q.","year":"2015","unstructured":"Liang Q.; Liu H.; Zhang T.; Jiang Y.; Xing H.; Zhang A.; Metabolomics-based screening of salivary biomarkers for early diagnosis of Alzheimer\u2019s disease. RSC Advances 2015,5(116),96074-96079","journal-title":"RSC Advances"},{"key":"ref=115","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.3390\/ijms18102205","volume":"18","year":"2017","unstructured":"Antioxidant defence, oxidative stress and oxidative damage in saliva, plasma and erythrocytes of dementia patients. Can salivary AGE be a marker of dementia. Int J Mol Sci 2017,18(10),2205","journal-title":"Int J Mol Sci"},{"key":"ref=116","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.3233\/JAD-180711","volume":"65","author":"Huan T.","year":"2018","unstructured":"Huan T.; Tran T.; Zheng J.; Metabolomics analyses of saliva detect novel biomarkers of Alzheimer\u2019s disease. J Alzheimers Dis 2018,65,1401-1406","journal-title":"J Alzheimers Dis"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"840","DOI":"10.3390\/jcm8060840","volume":"8","author":"Klimiuk A.","year":"2019","unstructured":"Klimiuk A.; Maciejczyk M.; Choroma\u0144ska M, Fejfer K, Waszkiewicz N, Zalewska A. Salivary redox biomarkers in different stages of dementia severity. J Clin Med 2019,8(6),840","journal-title":"J Clin Med"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.jpba.2018.11.043","volume":"164","author":"Pe\u00f1a-Bautista C.","year":"2019","unstructured":"Pe\u00f1a-Bautista C.; Carrascosa-Marco P.; Oger C.; Validated analytical method to determine new salivary lipid peroxidation compounds as potential neurodegenerative biomarkers. J Pharm Biomed Anal 2019,164,742-749","journal-title":"J Pharm Biomed Anal"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.3390\/jcm9061673","volume":"9","author":"Paraskevaidi M.","year":"2020","unstructured":"Paraskevaidi M.; Allsop D.; Karim S.; Martin F.L.; Crean S.; Diagnostic biomarkers for Alzheimer\u2019s disease using non-invasive specimens. J Clin Med 2020,9(6),1673","journal-title":"J Clin Med"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3233\/JAD-161226","volume":"58","author":"Yilmaz A.","year":"2017","unstructured":"Yilmaz A.; Geddes T.; Han B.; Diagnostic biomarkers of Alzheimer\u2019s disease as identified in saliva using 1H NMR-based metabolomics. J Alzheimers Dis 2017,58(2),355-359","journal-title":"J Alzheimers Dis"},{"key":"ref=121","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2021.668852","volume":"15","author":"Contini C.","year":"2021","unstructured":"Contini C.; Olianas A.; Serrao S.; Top-down proteomics of human saliva highlights anti-inflammatory, antioxidant, and antimicrobial defense responses in Alzheimer disease. Front Neurosci 2021,15","journal-title":"Front Neurosci"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"463","DOI":"10.3389\/fnins.2019.00463","volume":"13","author":"Crist\u00f3v\u00e3o J.S.","year":"2019","unstructured":"Crist\u00f3v\u00e3o J.S.; Gomes C.M.; S100 proteins in Alzheimer\u2019s disease. Front Neurosci 2019,13,463","journal-title":"Front Neurosci"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3390\/proteomes9010013","volume":"9","author":"Jain A.P.","year":"2021","unstructured":"Jain A.P.; Sathe G.; Proteomics landscape of Alzheimer\u2019s disease. Proteomes 2021,9(1),13","journal-title":"Proteomes"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13167-016-0065-3","volume":"7","author":"Hagan S.","year":"2016","unstructured":"Hagan S.; Martin E.; Enr\u00edquez-de-Salamanca A.; Tear fluid biomarkers in ocular and systemic disease: Potential use for predictive, preventive and personalised medicine. EPMA J 2016,7(1),15","journal-title":"EPMA J"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"3877","DOI":"10.1016\/j.jprot.2012.04.053","volume":"75","author":"Zhou L.","year":"2012","unstructured":"Zhou L.; Zhao S.Z.; Koh S.K.; In-depth analysis of the human tear proteome. J Proteomics 2012,75(13),3877-3885","journal-title":"J Proteomics"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1016\/S0140-6736(03)12981-9","volume":"361","author":"Goldstein L.E.","year":"2003","unstructured":"Goldstein L.E.; Muffat J.A.; Cherny R.A.; Cytosolic beta-amyloid deposition and supranuclear cataracts in lenses from people with Alzheimer\u2019s disease. Lancet 2003,361(9365),1258-1265","journal-title":"Lancet"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"8661","DOI":"10.3390\/ijms21228661","volume":"21","author":"Zhou B.","year":"2020","unstructured":"Zhou B.; Fukushima M.; Clinical utility of the pathogenesis-related proteins in Alzheimer\u2019s disease. Int J Mol Sci 2020,21(22),8661","journal-title":"Int J Mol Sci"},{"key":"ref=128","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0158000","volume":"11","author":"Kall\u00f3 G.","year":"2016","unstructured":"Kall\u00f3 G.; Emri M.; Varga Z.; Changes in the chemical barrier composition of tears in Alzheimer\u2019s disease reveal potential tear diagnostic biomarkers. PLoS One 2016,11(6)","journal-title":"PLoS One"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"12685","DOI":"10.1038\/s41598-017-12858-7","volume":"7","author":"Mirzaei M.","year":"2017","unstructured":"Mirzaei M.; Gupta V.B.; Chick J.M.; Age-related neurodegenerative disease associated pathways identified in retinal and vitreous proteome from human glaucoma eyes. Sci Rep 2017,7(1),12685","journal-title":"Sci Rep"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"15437","DOI":"10.1038\/s41598-019-51837-y","volume":"9","author":"Kenny A.","year":"2019","unstructured":"Kenny A.; Jim\u00e9nez-Mateos E.M.; Zea-Sevilla M.A.; Proteins and microRNAs are differentially expressed in tear fluid from patients with Alzheimer\u2019s disease. Sci Rep 2019,9(1),15437","journal-title":"Sci Rep"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1111\/bpa.12335","volume":"26","author":"Hern\u00e1ndez-Ortega K.","year":"2016","unstructured":"Hern\u00e1ndez-Ortega K.; Garcia-Esparcia P.; Gil L.; Lucas J.J.; Ferrer I.; Altered machinery of protein synthesis in Alzheimer\u2019s: From the nucleolus to the ribosome. Brain Pathol 2016,26(5),593-605","journal-title":"Brain Pathol"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1093\/brain\/aww205","volume":"139","author":"Tiwari S.S.","year":"2016","unstructured":"Tiwari S.S.; Mizuno K.; Ghosh A.; Alzheimer-related decrease in CYFIP2 links amyloid production to tau hyperphosphorylation and memory loss. Brain 2016,139(Pt 10),2751-2765","journal-title":"Brain"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"6131","DOI":"10.1007\/s11033-021-06585-6","volume":"48","author":"Biembengut I.V.","year":"2021","unstructured":"Biembengut I.V.; Silva I.L.Z.; Souza T.A.C.B.; Shigunov P.; Cytoplasmic FMR1 interacting protein (CYFIP) family members and their function in neural development and disorders. Mol Biol Rep 2021,48(8),6131-6143","journal-title":"Mol Biol Rep"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3389\/fgene.2018.00561","volume":"9","author":"Amorim I.S.","year":"2018","unstructured":"Amorim I.S.; Lach G.; Gkogkas C.G.; The role of the eukaryotic translation initiation factor 4E (eIF4E) in neuropsychiatric disorders. Front Genet 2018,9,561","journal-title":"Front Genet"},{"key":"ref=135","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.642420","volume":"12","author":"Agalave N.M.","year":"2021","unstructured":"Agalave N.M.; Mody P.H.; Szabo-Pardi T.A.; Jeong H.S.; Burton M.D.; Neuroimmune consequences of eIF4E phosphorylation on chemotherapy-induced peripheral neuropathy. Front Immunol 2021,12","journal-title":"Front Immunol"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"3112","DOI":"10.1002\/cne.25158","volume":"529","author":"Gindina S.","year":"2021","unstructured":"Gindina S.; Botsford B.; Cowansage K.; Upregulation of eIF4E, but not other translation initiation factors, in dendritic spines during memory formation. J Comp Neurol 2021,529(11),3112-3126","journal-title":"J Comp Neurol"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41398-020-00882-7","volume":"10","author":"Ghosh A.","year":"2020","unstructured":"Ghosh A.; Mizuno K.; Tiwari S.S.; Alzheimer\u2019s disease-related dysregulation of mRNA translation causes key pathological features with ageing. Transl Psychiatry 2020,10(1),192","journal-title":"Transl Psychiatry"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.semcdb.2020.09.005","volume":"114","author":"Jishi A.","year":"2021","unstructured":"Jishi A.; Qi X.; Miranda H.C.; Implications of mRNA translation dysregulation for neurological disorders. Semin Cell Dev Biol 2021,114,11-19","journal-title":"Semin Cell Dev Biol"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.4103\/1673-5374.308074","volume":"16","author":"Lu J.X.","year":"2021","unstructured":"Lu J.X.; Wang Y.; Zhang Y.J.; Axonal mRNA localization and local translation in neurodegenerative disease. Neural Regen Res 2021,16(10),1950-1957","journal-title":"Neural Regen Res"},{"key":"ref=140","first-page":"1","volume":"10","author":"Mofatteh M.","year":"2021","unstructured":"Mofatteh M.; Neurodegeneration and axonal mRNA transportation. Am J Neurodegener Dis 2021,10(1),1-12","journal-title":"Am J Neurodegener Dis"},{"key":"ref=141","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2021.697973","volume":"14","author":"Nagano S.","year":"2021","unstructured":"Nagano S.; Araki T.; Axonal transport and local translation of mRNA in neurodegenerative diseases. Front Mol Neurosci 2021,14","journal-title":"Front Mol Neurosci"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.3390\/biom11121807","volume":"11","author":"Merlo S.","year":"2021","unstructured":"Merlo S.; Spampinato S.F.; Lim D.; Molecular aspects of cellular dysfunction in Alzheimer\u2019s disease: The need for a holistic view of the early pathogenesis. Biomolecules 2021,11(12),1807","journal-title":"Biomolecules"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13024-021-00489-6","volume":"16","author":"Iatrou A.","year":"2021","unstructured":"Iatrou A.; Clark E.M.; Wang Y.; Nuclear dynamics and stress responses in Alzheimer\u2019s disease. Mol Neurodegener 2021,16(1),65","journal-title":"Mol Neurodegener"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"10283","DOI":"10.3390\/ijms221910283","volume":"22","author":"Gil L.","year":"2021","unstructured":"Gil L.; Ni\u00f1o S.A.; Guerrero C.; Jim\u00e9nez-Capdeville M.E.; Phospho-tau and chromatin landscapes in early and late Alzheimer\u2019s disease. Int J Mol Sci 2021,22(19),10283","journal-title":"Int J Mol Sci"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.3390\/biom11091261","volume":"11","author":"D\u2019Andrea L.","year":"2021","unstructured":"D\u2019Andrea L.; Stringhi R.; Di Luca M.; Marcello E.; Looking at Alzheimer\u2019s disease pathogenesis from the nuclear side. Biomolecules 2021,11(9),1261","journal-title":"Biomolecules"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"8726","DOI":"10.3390\/ijms22168726","volume":"22","author":"Sini P.","year":"2021","unstructured":"Sini P.; Dang T.B.C.; Fais M.; Cyanobacteria, cyanotoxins, and neurodegenerative diseases: dangerous liaisons. Int J Mol Sci 2021,22(16),8726","journal-title":"Int J Mol Sci"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"4423","DOI":"10.3390\/ijms22094423","volume":"22","author":"Piscopo P.","year":"2021","unstructured":"Piscopo P.; Bellenghi M.; Manzini V.; A sex perspective in neurodegenerative diseases: microRNAs as possible peripheral biomarkers. Int J Mol Sci 2021,22(9),4423","journal-title":"Int J Mol Sci"},{"key":"ref=148","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2021.754051","volume":"15","author":"Kujawska M.","year":"2021","unstructured":"Kujawska M.; Domanskyi A.; Kreiner G.; Editorial: Common pathways linking neurodegenerative diseases - The role of inflammation. Front Cell Neurosci 2021,15","journal-title":"Front Cell Neurosci"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"6055","DOI":"10.3390\/ijms20236055","volume":"20","author":"Konovalova J.","year":"2019","unstructured":"Konovalova J.; Gerasymchuk D.; Parkkinen I.; Chmielarz P.; Domanskyi A.; Interplay between microRNAs and oxidative stress in neurodegenerative diseases. Int J Mol Sci 2019,20(23),6055","journal-title":"Int J Mol Sci"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"7035","DOI":"10.1038\/s41467-021-27204-9","volume":"12","author":"Ma Y.","year":"2021","unstructured":"Ma Y.; Dammer E.B.; Felsky D.; Atlas of RNA editing events affecting protein expression in aged and Alzheimer\u2019s disease human brain tissue. Nat Commun 2021,12(1),7035","journal-title":"Nat Commun"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.3390\/genes12122005","volume":"12","author":"Nguyen L.D.","year":"2021","unstructured":"Nguyen L.D.; Chau R.K.; Krichevsky A.M.; Small molecule drugs targeting non-coding RNAs as treatments for Alzheimer\u2019s disease and related dementias. Genes (Basel) 2021,12(12),2005","journal-title":"Genes (Basel)"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s40291-021-00513-x","volume":"25","author":"Tsamis K.I.","year":"2021","unstructured":"Tsamis K.I.; Sakkas H.; Giannakis A.; Ryu H.S.; Gartzonika C.; Nikas I.P.; Evaluating infectious, neoplastic, immunological, and degenerative diseases of the central nerv\u00f1ous system with cerebrospinal fluid-based next-generation sequencing. Mol Diagn Ther 2021,25(2),207-229","journal-title":"Mol Diagn Ther"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"8368","DOI":"10.1038\/s41598-019-44848-2","volume":"9","author":"Giau V.V.","year":"2019","unstructured":"Giau V.V.; Bagyinszky E.; Yang Y.S.; Youn Y.C.; An S.S.A.; Kim S.Y.; Genetic analyses of early-onset Alzheimer\u2019s disease using next generation sequencing. Sci Rep 2019,9(1),8368","journal-title":"Sci Rep"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"4282","DOI":"10.1038\/s41598-018-22701-2","volume":"8","author":"Annese A.","year":"2018","unstructured":"Annese A.; Manzari C.; Lionetti C.; Whole transcriptome profiling of Late-onset Alzheimer\u2019s disease patients provides insights into the molecular changes involved in the disease. Sci Rep 2018,8(1),4282","journal-title":"Sci Rep"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"3517","DOI":"10.3390\/ijms21103517","volume":"21","author":"Bagyinszky E.","year":"2020","unstructured":"Bagyinszky E.; Giau V.V.; An S.A.; Transcriptomics in Alzheimer\u2019s disease: Aspects and challenges. Int J Mol Sci 2020,21(10),3517","journal-title":"Int J Mol Sci"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.3390\/cells10051030","volume":"10","author":"Lake J.","year":"2021","unstructured":"Lake J.; Storm C.S.; Makarious M.B.; Bandres-Ciga S.; Genetic and transcriptomic biomarkers in neurodegenerative diseases: Current situation and the road ahead. Cells 2021,10(5),1030","journal-title":"Cells"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"4820","DOI":"10.3390\/ijms22094820","volume":"22","author":"La Cognata V.","year":"2021","unstructured":"La Cognata V.; Morello G.; Cavallaro S.; Omics data and their integrative analysis to support stratified medicine in neurodegenerative diseases. Int J Mol Sci 2021,22(9),4820","journal-title":"Int J Mol Sci"},{"key":"ref=158","doi-asserted-by":"publisher","DOI":"10.1016\/j.nicl.2020.102290","volume":"27","author":"Gao F.","year":"2020","unstructured":"Gao F.; Yoon H.; Xu Y.; AD-NET: Age-adjust neural network for improved MCI to AD conversion prediction. Neuroimage Clin 2020,27","journal-title":"Neuroimage Clin"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.3390\/diagnostics11081473","volume":"11","author":"Fabrizio C.","year":"2021","unstructured":"Fabrizio C.; Termine A.; Caltagirone C.; Sancesario G.; Artificial intelligence for Alzheimer\u2019s disease: Promise or challenge? Diagnostics (Basel) 2021,11(8),1473","journal-title":"Diagnostics (Basel)"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"3479","DOI":"10.3390\/cells10123479","volume":"10","author":"Tasker R.","year":"2021","unstructured":"Tasker R.; Rowlands J.; Ahmed Z.; Di Pietro V.; Co-expression network analysis of micro-RNAs and proteins in the Alzheimer\u2019s brain: A systematic review of studies in the last 10 years. Cells 2021,10(12),3479","journal-title":"Cells"},{"key":"ref=161","unstructured":"Alzheimer\u2019s Disease Data Initiative (ADDI)Available from: Accessed on January 26, 2022"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41531-020-00125-y","volume":"6","author":"Pierce S.E.","year":"2020","unstructured":"Pierce S.E.; Booms A.; Prahl J.; van der Schans E.J.C.; Tyson T.; Coetzee G.A.; Post-GWAS knowledge gap: The how, where, and when. NPJ Parkinsons Dis 2020,6(1),23","journal-title":"NPJ Parkinsons Dis"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s12951-021-00864-x","volume":"19","author":"Cano A.","year":"2021","unstructured":"Cano A.; Turowski P.; Ettcheto M.; Nanomedicine-based technologies and novel biomarkers for the diagnosis and treatment of Alzheimer\u2019s disease: From current to future challenges. J Nanobiotechnology 2021,19(1),122","journal-title":"J Nanobiotechnology"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"791","DOI":"10.3390\/mi11090791","volume":"11","author":"Le H.T.N.","year":"2020","unstructured":"Le H.T.N.; Park J.; Cho S.; A probeless capacitive biosensor for direct detection of amyloid beta 1-42 in human serum based on an interdigitated chain-shaped electrode. Micromachines (Basel) 2020,11(9),791","journal-title":"Micromachines (Basel)"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"S109","DOI":"10.3233\/JAD-201074","volume":"82","author":"Merelli A.","year":"2021","unstructured":"Merelli A.; Repetto M.; Lazarowski A.; Auzmendi J.; Hypoxia, oxidative stress, and inflammation: Three faces of neurodegenerative diseases. J Alzheimers Dis 2021,82(s1),S109-S126","journal-title":"J Alzheimers Dis"},{"key":"ref=166","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2020.101138","volume":"63","author":"Scassellati C.","year":"2020","unstructured":"Scassellati C.; Galoforo A.C.; Bonvicini C.; Esposito C.; Ricevuti G.; Ozone: A natural bioactive molecule with antioxidant property as potential new strategy in aging and in neurodegenerative disorders. Ageing Res Rev 2020,63","journal-title":"Ageing Res Rev"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1007\/s00204-019-02538-y","volume":"93","author":"Simunkova M.","year":"2019","unstructured":"Simunkova M.; Alwasel S.H.; Alhazza I.M.; Management of oxidative stress and other pathologies in Alzheimer\u2019s disease. Arch Toxicol 2019,93(9),2491-2513","journal-title":"Arch Toxicol"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s00210-020-01963-6","volume":"394","author":"Imai T.","year":"2021","unstructured":"Imai T.; Tsuji S.; Matsubara H.; Deferasirox, a trivalent iron chelator, ameliorates neuronal damage in hemorrhagic stroke models. Naunyn Schmiedebergs Arch Pharmacol 2021,394(1),73-84","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"}],"container-title":["Current Pharmaceutical Design"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1381612828666220413101929","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/203491\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1381612828666220413101929","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T01:25:15Z","timestamp":1700443515000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/203491\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":168,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1381612828666220413101929","relation":{},"ISSN":["1381-6128"],"issn-type":[{"value":"1381-6128","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-10-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}